期刊
CANCER RESEARCH
卷 74, 期 24, 页码 7333-7343出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-13-3572
关键词
-
类别
资金
- NSC [NSC99-2320-B-010-020-MY3]
- Ministry of Education, Aim for the Top University Plan [100AC-T402, 101AC-T402, 102AC-T402, 103AC-T610]
- American Cancer Society Institutional Research grant
- Purdue University Center for Cancer Research [IRG 58-006-53]
- Purdue startup fund
Aberrant histone methylation is a frequent event during tumor development and progression. KMT1E (also known as SETDB1) is a histone H3K9 methyltransferase that contributes to epigenetic silencing of both oncogenes and tumor suppressor genes in cancer cells. In this report, we demonstrate that KMT1E acts as a metastasis suppressor that is strongly downregulated in highly metastatic lung cancer cells. Restoring KMT1E expression in this setting suppressed filopodia formation, migration, and invasive behavior. Conversely, loss of KMT1E in lung cancer cells with limited metastatic potential promoted migration in vitro and restored metastatic prowess in vivo. Mechanistic investigations indicated that KMT1E cooperates with the TGF beta-regulated complex SMAD2/3 to repress metastasis through ANXA2. Together, our findings defined an essential role for the KMT1E/SMAD2/3 repressor complex in TGF beta-mediated lung cancer metastasis. (C)2014 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据